VITAMIN D (ergocalciferol) by Molecular Devices is clinical pharmacology the in vivo synthesis of the major biologically active metabolites of vitamin d occurs in two steps. First approved in 1973.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1, 25-dihydroxyvitamin D). Vitamin D metabolites…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Vitamin D and Type 2 Diabetes - Treat-To-Target
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
Assessment of the Remineralization Efficacy of Vitamin D in the Treatment of MIH and Its Role in Improving Oral Hygiene and Gingival Health. In Situ Randomized Double-Blind Placebo CT
Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl
Evaluation of a Nutritional Technology for Vitamin D Absorption
Worked on VITAMIN D at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.